Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European Leukemianet MRD Working Party

Jesse M Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B Walter, Brent L Wood, Christophe Roumier, Jan Philippé, Barbara Denys, Jeffrey L Jorgensen, Marie C Bene, Francis Lacombe, Adriana Plesa, Monica L Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian SchwarzerCosta Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano

Research output: Contribution to journalArticlepeer-review

9 Downloads (Pure)

Abstract

Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.

Original languageEnglish
Article numbere676
Number of pages11
JournalHemaSphere
Volume6
Issue number1
Early online date22 Dec 2021
DOIs
Publication statusPublished - Jan 2022

Bibliographical note

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

Fingerprint

Dive into the research topics of 'Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European Leukemianet MRD Working Party'. Together they form a unique fingerprint.

Cite this